Pulse Biosciences (NASDAQ:PLSE) Trading 5.2% Higher – What’s Next?

Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) traded up 5.2% during mid-day trading on Tuesday . The company traded as high as $18.52 and last traded at $18.53. 11,517 shares changed hands during trading, a decline of 90% from the average session volume of 113,105 shares. The stock had previously closed at $17.61.

Analyst Ratings Changes

Separately, StockNews.com raised Pulse Biosciences to a “sell” rating in a research report on Thursday, January 2nd.

Pulse Biosciences Trading Down 4.8 %

The business has a 50-day moving average price of $18.29 and a two-hundred day moving average price of $17.65.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) EPS for the quarter. During the same period in the previous year, the firm earned ($0.19) earnings per share.

Insider Transactions at Pulse Biosciences

In related news, CEO Burke Thomas Barrett sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total transaction of $871,000.00. Following the completion of the sale, the chief executive officer now owns 63,172 shares in the company, valued at approximately $1,100,456.24. This trade represents a 44.18 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Robert W. Duggan bought 55,256 shares of the company’s stock in a transaction on Friday, December 13th. The stock was bought at an average price of $17.18 per share, for a total transaction of $949,298.08. Following the completion of the purchase, the director now owns 42,328,717 shares of the company’s stock, valued at approximately $727,207,358.06. The trade was a 0.13 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 71.50% of the company’s stock.

Institutional Investors Weigh In On Pulse Biosciences

Several institutional investors have recently added to or reduced their stakes in PLSE. Charles Schwab Investment Management Inc. increased its position in shares of Pulse Biosciences by 193.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock valued at $2,598,000 after buying an additional 97,565 shares during the period. State Street Corp grew its stake in Pulse Biosciences by 17.8% during the third quarter. State Street Corp now owns 461,333 shares of the company’s stock valued at $8,092,000 after acquiring an additional 69,696 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Pulse Biosciences during the 3rd quarter worth approximately $588,000. Geode Capital Management LLC lifted its stake in Pulse Biosciences by 7.8% in the 3rd quarter. Geode Capital Management LLC now owns 457,165 shares of the company’s stock worth $8,020,000 after purchasing an additional 33,200 shares in the last quarter. Finally, Barclays PLC boosted its holdings in Pulse Biosciences by 361.4% in the 3rd quarter. Barclays PLC now owns 30,306 shares of the company’s stock valued at $530,000 after purchasing an additional 23,738 shares during the period. 76.95% of the stock is owned by hedge funds and other institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.